Cancer Genetics and Epigenetics – Gordon Research Conference
To present my research findings at this highly relevant research conference. This work was carried out over the last 1.5 years in Christchurch (University of Otago), and has some exciting implications for patients with Acute Myeloid Leukaemia. As such, it will provide a great opportunity for research done in Canterbury to have a wider impact. These findings actually provided inspiration for the current CMRF funded project I am working on. Attendance at this conference will also be a great opportunity for me to get input from key players in the cancer epigenetics field, particularly those with expertise in leukaemia.
Dr Das is interested in the role that metabolism and epigenetics play in the development of cancer. Together with Professor Margreet Vissers, he is currently investigating the potential use of ascorbate (vitamin C) as an epigenetic therapeutic for specific subtypes of acute myeloid leukaemia (AML).More About Dr Andrew Das